Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003

Catheterization and Cardiovascular Interventions

Volumn 67, Issue 4, 2006, Pages 556-562

  Applegate, Robert J ^a   Sacrinty, Matthew T ^a   Kutcher, Michael A ^a   Baki, Talal T ^a   Gandhi, Sanjay K ^a   Santos, Renato M ^a   Little, William C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac catheterization; Percutaneous coronary intervention; Propensity analysis; Vascular complications

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TICLOPIDINE;

ADULT; AGED; ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; COVARIANCE; DEVICE; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE ANALYSIS; SAFETY; STATISTICAL ANALYSIS; VASCULAR ACCESS; VASCULAR CLOSURE DEVICE; VASCULAR DISEASE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VASCULAR DISEASES;

EID: 33646025544     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20677     Document Type: Article

References (21)

1. Kussmaul WGI, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: Results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol 1995;25:1685-1692.
2. Duffin DC, Muhlestein JB, Allison SB, Home BD, Fowles RE, Sorensen SG, Revenaugh JR, Bair TL, Lappe DL. Femoral arterial puncture management after percutaneous coronary procedures: A comparison of clinical outcomes and patient satisfaction between manual compressions and two different vascular closure devices. J Invasive Cardiol 2001;13:354-362.
3. Nasu K, Tsuchikane E, Sumitsuji S. The clinical effectiveness of the Prostar XL suture mediated percutaneous vascular closure device for achievement of hemostasis in patients following coronary interventions: Results of the Perclose accelerated ambulation and discharge (Paradise) trial. J Invasive Cardiol 2003;15: 251-256.
4. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis. JAMA 2004;291:350-357.
5. Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: A meta-analysis. J Am Coll Cardiol 2004;44:1200-1209.
6. Applegate RJ, Grabarczyk MA, Little WC, Craven T, Walkup M, Kahl FR, Braden GA, Rankin KM, Kutcher MA. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol 2002;40:78-83.
7. American College of Cardiology Website. American College of Cardiology-National Cardiovascular Data Registry Module Version 3.0. www.acc.org/ncdr/pdfs/download_3_0dataonly.pdf. American College of Cardiology, 2003.
8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
9. D'Agostino RB. Tutorial in biostatistics-propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
10. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109:2290-2295.
11. Kresowik TF, Khoury MD, Miller BV, Winniford MD, Shamma AR, Sharp WJ, Blecha MB, Corson JD. A prospective study of the incidence and natural history of femoral vascular complications after percutaneous transluminal coronary angioplasty. J Vasc Surg 1991;13:328-336.
12. Konstance R, Tcheng JE, Wightman MB, Kelly LP, Moore A, Harrison JK, Sketch MH Jr. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. J Interv Cardiol 2004;17:65-70.
13. Omoigui NA, Califf RM, Pieper K, Keeler G, O'Hanesian MD, Berdan LG, Mark DB, Talley JD, Topol EJ. Peripheral vascular complications in the coronary angioplasty versus excisional atherectomy trial (CAVEAT-1). J Am Coll Cardiol 1995;26:922-930.
14. Piper WD, Malenka DJ, Ryan TJ Jr, Shubrooks SJ Jr, O'Connor GT, Robb JF, Farrell KL, Corliss MS, Hearne MJ, Kellett MA Jr, et al. for the Northern New England Cardiovascular Disease Study Group. Predicting vascular complications in percutaneous coronary interventions. Am Heart J 2003;145:1022-1029.
15. Waksman R, King SB III, Douglas JS, Shen Y, Ewing H, Mueller L, Ghazzal ZMB, Weintraub WS. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol 1995;75:886-889.
16. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, Coady P, Cohen H, Cowley M, Dorros G, et al. for the Coinvestigators. Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute Registries. Circulation 2000;102:2945-2951.
17. Assali AR, Sdringola S, Moustapha A, Ghani M, Salloum J, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices. Catheter Cardiovasc Interv 2003;58:1-5.
18. Resnic FS, Blake GJ, Ohno-Machado L, Selwyn AP, Popma JJ, Rogers C. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. Am J Cardiol 2001; 88:493-96.
19. Tavris D, Gross T, Gallauresi B, Kessler L. Arteriotomy closure devices-The FDA perspective (editorial). J Am Coll Cardiol 2001; 38:642-644.
20. Tavris DR, Gallauresi BA, Lin B, Rich SE, Shaw RE, Weintraub WS, Brindis RG, Hewitt K. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol 2004;16:459-464.
21. Rickli H, Unterweger M, Sutsch G, Brunner-La Rocca HP, Sagmeister M, Ammann P, Amann FW. Comparison of costs and safety of a suture-mediated closure device with conventional manual compression after coronary artery interventions. Catheter Cardiovasc Interv 2002;57:297-302.